News Related to Gossamer Bio

Related coverage linked through entity extraction aliases.

Seralutinib Shows Mixed Results in Phase 3 PAH Trial, Winrevair Benefits Heart Failure-Related PH

Apr 02, 2026

Phase 3 trial results show seralutinib missed its primary endpoint in PAH but showed benefit in advanced disease subgroups. Meanwhile, Winrevair demonstrated significant reductions in pulmonary vascular resistance in heart failure-related pulmonary hypertension in a Phase 2 study.

Gossamer Bio's Seralutinib Misses Primary Endpoint in Phase 3 PAH Trial

Feb 23, 2026

Gossamer Bio's seralutinib narrowly missed its primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension, achieving a p-value of 0.0320 versus the prespecified threshold of 0.025, though showing stronger results in intermediate- and high-risk patients.